- Sermorelin is the one growth hormone releasing peptide with a prior FDA approval behind it, which is why it still has a working compounding route in 2026 while CJC-1295 comes under pressure.
- Published protocols start at 200 to 350 mcg injected under the skin before bed (chart by body weight below), recheck IGF-1 at 4 to 6 weeks, and adjust in 50 mcg steps toward 180 to 260 ng/mL.
- A 2026 meta-analysis in Obesity Research and Clinical Practice pooled five trials and found an average 1.42 kg gain in lean mass, concentrated in participants who trained at least three times a week.
- Clinical schedules run 5 nights on, 2 nights off. Dosing every night for more than 6 to 8 weeks starts flattening the hormone pulse. Cycle off for 4 to 8 weeks after 6 months.
- Body weight tells you where to start, not where you will land. Two people at the same weight can end up at very different doses, and only a blood test at 6 weeks tells you which one you are.
Most sermorelin dosage guides give you a flat "200-500 mcg nightly" range and call it done. That range is not wrong. But the 72-week study that produced the largest results, 2.1 kg of lean mass and a 6.3% cut in the deep fat around the organs, did not use a flat range. It adjusted the dose at week 6 based on a blood test, and every participant lifted weights three times a week. Strip out those two things and lean mass gain from this class of peptide drops to noise in the published literature. The dose alone is not the protocol.
Sermorelin carries an FDA review history going back to its 1997 approval as Geref. No other growth hormone releasing peptide currently reachable through a compounding pharmacy has that behind it.
Sermorelin is a lab-made copy of the first 29 amino acids of growth hormone releasing hormone, the signal your hypothalamus sends to your pituitary. It docks onto the same receptor and triggers a burst of growth hormone: the natural signal, delivered on a schedule you choose. Synthetic HGH does something different, flooding your system with a flat, constant level. Sermorelin keeps the burst-and-pause rhythm the rest of the system is built around, which is why it tends to cause fewer problems with receptors going deaf over months of use.
In 2024-2026, as FDA scrutiny on CJC-1295 increased and compounding pharmacy access to that peptide narrowed, sermorelin became the default GHRH analog for 503A clinics. If you are considering GHRH therapy in 2026, this is where most protocols begin.
Think of sermorelin as a scheduled alarm that rings your pituitary at bedtime. The pituitary releases GH for a short burst, then the signal disappears within hours. CJC-1295 with Drug Affinity Complex is more like leaving the alarm on continuously for 7-10 days. Sermorelin works with your body's existing rhythm. CJC-1295 overrides it. Both increase IGF-1, but the receptor implications over months of use are very different.
What Sermorelin Actually Does: The Results From 20 Years of Trials
Adults with low-normal IGF-1 (baseline below 150 ng/mL) see IGF-1 increases of 40-80% within the first 4-6 weeks of a standard sermorelin protocol. In participants who were already in the normal range, the increase is more modest: 20-40%. A 2026 meta-analysis by Badran and Helal in Obesity Research and Clinical Practice pooled five randomized controlled trials of GHRH analogs and confirmed a mean 1.42 kg increase in lean mass across all participants. The subgroup that combined peptide therapy with resistance training showed significantly larger lean mass gains.
"GHRH analog therapy produced meaningful lean mass gains only in participants who maintained structured resistance exercise. The peptide amplifies the anabolic signal from training, it does not create lean mass in the absence of that stimulus."
Badran and Helal, Obesity Research and Clinical Practice, 2026 meta-analysis of five GHRH analog RCTs
A 2025 review in the Journal of Stem Cell Research identified sermorelin as the lowest-risk entry point in the GHRH peptide class for healthy adults seeking anabolic and regenerative effects. The reviewers noted strong data on soft tissue repair and recovery alongside meaningful body composition effects, while flagging the absence of large-scale RCTs specific to sermorelin (as opposed to GHRH analogs generally) as the primary evidence gap compared to tesamorelin, the only FDA-approved GHRH peptide.
The "well, actually" moment most guides skip over: studies on GHRH analogs that did not require participants to train produced near-zero lean mass benefit on average. The peptide is an amplifier. It amplifies whatever anabolic signal already exists from your training. If that signal is absent, there is nothing to amplify. Sermorelin without consistent training is paying for a gym membership and never going.
Week-by-Week Timeline: What You Will Actually Feel
IGF-1 elevations show up in blood tests before they show up in the mirror. Here is a realistic timeline based on the clinical data and what users consistently report.
| Timeframe | What Changes | What to Track |
|---|---|---|
| Week 1-2 | Sleep depth improves, vivid dreams return, morning energy increases | Sleep quality, morning mood |
| Week 3-4 | Recovery between training sessions accelerates, less delayed soreness | Soreness duration, training performance |
| Week 5-6 | IGF-1 reaches new baseline (draw morning fasted labs now) | IGF-1 blood test, titrate dose based on result |
| Week 8-12 | Visible lean mass and body composition changes begin | Waist circumference, body fat percentage |
| Month 4-6 | Full lean mass benefit accumulates (1.42 kg average per meta-analysis) | DEXA scan if available, re-check IGF-1 |
| Month 6 | Cycle off for 4-8 weeks to allow receptor resensitization | Allow natural GH axis to recalibrate before next cycle |
Sermorelin Dosage Chart by Body Weight: Where to Start
Body weight determines your starting dose. It does not determine your final dose. The 6-week IGF-1 test is what does that. Use the chart below as your week-1 baseline, then titrate based on where your IGF-1 lands.
| Body Weight | Starting Dose | After 6-Week IGF-1 Test | Max Dose |
|---|---|---|---|
| Under 70 kg (154 lbs) | 200 mcg/night | Hold at 200 if IGF-1 is 180-260; add 50 mcg if below 180 | 350 mcg |
| 70-90 kg (154-198 lbs) | 250 mcg/night | Hold at 250 if IGF-1 is 180-260; add 50 mcg if below 180 | 400 mcg |
| 90-110 kg (198-242 lbs) | 300 mcg/night | Hold at 300 if IGF-1 is 180-260; add 50 mcg if below 180 | 500 mcg |
| Over 110 kg (242+ lbs) | 350 mcg/night | Hold at 350 if IGF-1 is 180-260; add 50 mcg if below 180 | 500 mcg |
Timing rule: Subcutaneous injection 30-60 minutes before bed. Sleep is when your natural GH pulse is largest. Sermorelin amplifies this pulse, not a daytime one. Eating within 2 hours before injection triggers somatostatin release that blunts GH output significantly. Fast for at least 2 hours before your dose.
Frequency rule: 5 nights on, 2 nights off. Clinical protocols use this schedule specifically to prevent receptor downregulation. Daily dosing for 6-8 weeks straight begins compressing the GH pulse magnitude as GHRH receptors gradually desensitize. The two off-nights per week allow partial resensitization and maintain the effectiveness of each dose through the full 6-month cycle. For the full receptor biology behind this, see our article on how long GH receptors take to reset after a peptide cycle.
Standard Protocol (Body Composition)
- Dose: 200-500 mcg subcutaneous, weight-based
- Timing: 30-60 minutes before bed, 2-hour food fast
- Frequency: 5 nights on, 2 nights off
- Cycle length: 6 months on, 4-8 weeks off
- First IGF-1 draw: 4-6 weeks in (morning, fasted)
- Target IGF-1: 180-260 ng/mL (age-adjusted)
Maintenance Protocol (Anti-Aging)
- Dose: 100-200 mcg subcutaneous, weight-based
- Timing: 30-60 minutes before bed, 2-hour food fast
- Frequency: 5 nights on, 2 nights off (or 3 on, 4 off)
- Cycle length: Year-round at lower doses with quarterly IGF-1 monitoring
- Target IGF-1: Age-appropriate low-normal range
- Re-evaluate: Every 3 months
Why Sermorelin Is Legal and CJC-1295 Is Increasingly Not
Most people searching for sermorelin dosage are really asking a second question: is sermorelin actually worth switching to from CJC-1295?
Sermorelin was FDA-approved as Geref in 1997 for diagnosing GH deficiency in children. The commercial product was withdrawn in 2008, not for safety reasons, but because synthetic HGH had taken over the market. That approval history gives sermorelin something no newer GHRH analog can claim: an established safety review record at the agency level. When the FDA evaluates whether a peptide is appropriate for 503A compounding, prior approval is a significant factor.
CJC-1295 was never FDA-approved. In late 2024, an FDA advisory committee review increased scrutiny on novel peptides that lacked prior approval history. CJC-1295, particularly the Drug Affinity Complex (DAC) version with its 7-10 day half-life, came under significantly more pressure under 503B outsourcing facility rules. Most major 503A compounding pharmacies pivoted their GHRH analog business to sermorelin as a result. For a full comparison of how sermorelin sits against other GH peptides on regulatory and evidence grounds, see the tesamorelin vs MK-677 vs CJC-1295 comparison.
The practical consequence in 2026: a January FDA guidance introduced prescriber attestation requirements before 503B facilities will compound sermorelin, which pushed standard 3 mg vial prices to $220-$310 (up from $180-$240 in late 2025). Sermorelin got more expensive. It did not get inaccessible. That distinction matters if you are planning a 6-month cycle. The comparison with ipamorelin vs CJC-1295 is worth reading to understand the full picture of what changed in the GH peptide compounding landscape and why.
Average lean mass increase across five randomized controlled trials of GHRH analogs, per the 2026 Badran and Helal meta-analysis. The effect was significantly larger in the subgroup that maintained resistance training at least three times weekly throughout the study period.
How Long Should You Run Sermorelin Before Cycling Off?
The standard answer is 6 months on, 4-8 weeks off. The receptor biology is the reason.
Sermorelin's short half-life means it does not continuously stimulate pituitary GHRH receptors the way CJC-1295 with DAC does. The 5-on/2-off weekly schedule already provides partial receptor recovery. A full 6-month cycle at this frequency tends not to produce significant desensitization if the weekly schedule is respected. Injectable GHRPs like hexarelin or GHRP-2 desensitize within 7-14 days of daily dosing. Sermorelin on the 5/2 schedule is far more forgiving.
The signal to watch is not time but IGF-1 trend. If your IGF-1 was stable at 220 ng/mL through week 12 and drops to 170 ng/mL by week 18 on the same dose, that is the receptor going deaf. In that case, drop to 3 nights per week for 4 to 6 weeks before cycling off completely, rather than pushing the dose up to compensate. More signal into a receptor that has stopped listening does not recover the response; it deepens the problem.
Why two people at the same weight end up on different doses
Body weight sets where you start. What decides where you finish is how well the signal lands, and that is partly inherited.
The first factor is how many docking points you have. GHRHR is the receptor on your pituitary that sermorelin binds to trigger a hormone burst, and variants that leave you expressing fewer of them mean each dose has less to grip. People in that position often plateau at a lower IGF-1 no matter how much the dose climbs. That is a ceiling, not a failed protocol, and the practical use of knowing it is that you stop chasing a number your biology will not produce.
The second factor is what happens downstream, and here the popular version of the story is wrong. GHR is the receptor growth hormone itself lands on, and a common version of it is missing a small section, known as the exon 3 deletion or d3. It is widely claimed that carrying it doubles your IGF-1 response and that carriers should therefore start low. The best test of that is Moyes and colleagues (PMID 20039885), who put 194 adults on an identical protocol: people with two d3 copies did show a bigger IGF-1 change at 12 months, but they ended up needing no different a maintenance dose, and the authors concluded that the variant does not explain the wide variation in response. The honest position is that it is a reason to draw your first blood test early rather than a reason to change your starting dose. Our article on GHR exon 3 deletion and peptide response goes through the evidence in full.
If you want to know where your ceiling sits before committing to a 6-month cycle, a full sermorelin genetic match from your DNA data is the shortcut.
Verdict
Sermorelin is the best-documented growth hormone releasing peptide still reachable through a compounding pharmacy in 2026, and it sits in a regulatory position CJC-1295 increasingly cannot match. The weight-based chart gets you started. The blood test at 6 weeks tells you where your own ceiling is. The training is not optional: every study showing 1.42 to 2.1 kg of lean mass required structured resistance exercise.
To know what your genetics support before spending six months guessing at a dose, upload your genetic data for a matched peptide report. If you have never had your DNA read, we will point you to a testing partner.
Frequently asked questions
How long does sermorelin take to work?
Sleep quality and morning energy typically improve within 1-2 weeks, as GH has a direct effect on slow-wave sleep architecture. Recovery between training sessions accelerates by week 3-4. Visible body composition changes take 8-12 weeks. The full lean mass benefit documented in the clinical literature (averaging 1.42 kg in a 2026 meta-analysis) accumulates over 4-6 months of consistent use with resistance training.
What is the best time of day to take sermorelin?
30-60 minutes before bed, with at least a 2-hour food fast beforehand. Your natural GH pulse is largest during the first few hours of sleep. Sermorelin amplifies this pulse rather than creating a new one at an arbitrary time. Eating within 2 hours before dosing triggers somatostatin release that significantly blunts GH output per injection.
Can you take sermorelin every day?
Clinical protocols use a 5-nights-on, 2-nights-off schedule rather than daily dosing. Continuous daily use for 6-8 weeks starts compressing the GH pulse magnitude as GHRH receptors gradually desensitize. The two weekly off-nights allow partial receptor resensitization and maintain the effectiveness of each dose across a full 6-month cycle. Daily dosing is not dangerous, but it reduces the return on each injection.
Does sermorelin spike cortisol like GHRP-2?
No. Sermorelin works through the growth hormone releasing hormone receptor, not the ghrelin receptor that GHRP-2 and hexarelin use, and it is that second receptor where the stress-hormone side effect comes from. At clinical doses sermorelin produces a clean growth hormone burst without meaningfully raising cortisol or the pituitary signal that drives it.
What should my IGF-1 be on sermorelin?
The standard clinical target is 180-260 ng/mL, adjusted for age. Adults over 60 generally target the lower end (around 180-200 ng/mL). Below 180 ng/mL at your 6-week test suggests a 50 mcg dose increase is warranted. Above 300 ng/mL suggests reducing dose or extending your weekly off-days before the next adjustment. Test in the morning, fasted, for a consistent baseline.
Can you stack sermorelin with ipamorelin?
Yes. Sermorelin (a GHRH analog) and ipamorelin (a GHRP) act on completely different receptors and produce a synergistic GH pulse when combined. The standard combination is 200-300 mcg sermorelin plus 200-300 mcg ipamorelin, both administered 30-60 minutes before bed. This combination became more popular as the CJC-1295 plus ipamorelin stack became harder to access through compounding.
Is sermorelin legal in the US in 2026?
Yes, with a prescription from a licensed physician. Sermorelin is not a scheduled substance and is available through 503A compounding pharmacies. A January 2026 FDA guidance introduced prescriber attestation requirements that added a documentation step for clinics, which pushed prices up 20-35% in early 2026. But the 503A pathway remains intact. CJC-1295 is in a more precarious position, which is why most clinics now default to sermorelin for GHRH therapy.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.